Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.41 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28841769 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2MAPK1LMNA | |
| SCHEMBL20059145 | 0.94 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL17403979 | 0.94 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL15003930 | 0.94 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL28855001 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL28854978 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL28854876 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL28854836 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL28854955 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 | |
| SCHEMBL26277080 | 0.92 | MGLL (0.46) | ALDH1A1MAPTLMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4107164-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| WO-2013084165-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-20130143835-A1 | HCV Polymerase Inhibitors | MEDIVIR AB (SE) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | ALDH1A1 744/4885MAPT 4373/4885SMN1; SMN2 111/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-20130143835-A1 | HCV Polymerase Inhibitors | POLI, HAVCR2, EIF2AK2 | ALDH1A1 362/4885MAPT 3533/4885SMN1; SMN2 4357/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885MAPT 2729/4885SMN1; SMN2 234/4885 |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | POLI, HAVCR2, EIF2AK2 | ALDH1A1 362/4885MAPT 3533/4885SMN1; SMN2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.